SLC5A2 and chronic kidney disease: Clinicians should be aware that people who have SGLT-2 inhibitors prescribed for diabetes are more likely to develop EDKA than those using SGLT-2 inhibitors for heart failure or chronic kidney disease treatment, as mentioned above.